ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

Haematologica. 2024 Oct 1;109(10):3419-3425. doi: 10.3324/haematol.2024.285410.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alleles*
  • DNA-Binding Proteins* / genetics
  • Dioxygenases*
  • Female
  • Genotype
  • Humans
  • Leukemia, Myelomonocytic, Chronic* / genetics
  • Male
  • Mutation*
  • Prognosis
  • Proto-Oncogene Proteins* / genetics
  • Repressor Proteins* / genetics
  • Risk Assessment

Substances

  • ASXL1 protein, human
  • Repressor Proteins
  • Dioxygenases
  • TET2 protein, human
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins

Grants and funding

Funding: This work was funded in part by the Mayo Foundation for Education and Research.